Founded in 2003, AMELAF represents 43 Mexican companies that operate 62 pharmaceutical plants throughout Mexico.
AMELAF works to influence public policies to the benefit of Mexico and its pharmaceutical industry.
The Association promotes a pharmaceutical industry that is responsible and trustworthy: Mexican laboratories that produce high-quality generic medicines that are safe, effective, and affordable for Mexico's population.
AMELAF is a nonprofit organization that represents and provides legal certainty to pharmaceutical plants of 100% Mexican ownership, that manufacture and sell medicines in Mexico.
AMELAF members are a group of Mexican laboratories that are committed to Mexico. Their objective is to manufacture medicines of high quality that are efficacious and safe, so that Mexican families have the real possibility of accessing medical treatment.
We have challenges ahead of us. The pharmaceutical industry has gained strength, creating jobs while developing into a difficult, competitive market with a view always to price and quality. AMELAF's member laboratories believe in Mexico and will continue to join forces to grow, to reinvest in favor of employment, and to contribute to improving the health of the Mexican people.
ARTURO MORALES PORTAS
AMELAF defends the interests of Mexico's pharmaceutical industry and works to expand the Association as the predominant organization of its kind in the pharmaceutical sector.
AMELAF promotes the consolidation of the pharmaceutical industry that is 100% Mexican- owned. This industry, the main supplier of medicines in the public sector, has two major challenges:
1. The tendency of the large transnational corporations to continue monopolizing the pharmaceutical market with high-priced products, and to block the entry of generic medicines that are now more attractive and profitable due to their rapid growth in Mexico.
2. Health regulations in Mexico, which are constantly modified to comply with the best international practices of health authorities.
AMELAF maintains communication and presence with authorities and institutions in Mexico's health and economic sector, in order to address topics of interest and impact for the domestic pharmaceutical industry. Permanent dialogue and communication have also been established with the health commissions of the Chamber of Deputies and Senate.
1. POINT OF CONTACT
AMELAF serves as its members' point of contact with the authorities and institutions of the nation's health sector, as well as with the health commissions of the Chamber of Deputies and Senate.
Information is transmitted in a daily compilation of the most important news items in the health sector, with emphasis on pharmaceutical topics and the news stories that present AMELAF's viewpoints and opinions.
To health and regulatory authorities, AMELAF provides information about regulations and information generated daily (Official Mexican Standards, reforms to laws and regulations, and notifications from COFEPRIS).
AMELAF reports on the bidding processes for purchasing health sector inputs.
It provides timely information on any topic that is considered relevant and may be of interest for its member laboratories.
AMELAF offers courses, workshops, and working groups of interest for Mexico's pharmaceutical industry, to provide Association members with training.
AMELAF reviews and analyzes the regulations published daily in Mexico's Official Gazette, on the COFEPRIS website, the CONAMER website, the IMPI Gazette of Medical Patents, and other standards of the domestic pharmaceutical industry.
Through a group of professionals specialized in international law and the pharmaceutical industry, AMELAF prepares the legal analysis of topics that affect corporate decisions in copyrights, and the regulations of international treaties and agreements, including United States-Mexico-Canada Agreement (USMCA), and the Free Trade Agreement between Mexico and the European Union (FTA EU-MX).
AMELAF provides guidance on the registration of medicines, health licenses, certification of good manufacturing practices, import permits, and advertising, with relation to COFEPRIS.
In recent times, mention has been made of the rejection of corruption in all spheres, both public and private. AMELAF agrees fully with this position.
Companies and institutions must invest in attaining a culture of integrity that will prevent any noncomplying practice. In parallel form, they must implement mechanisms of transparency and the rendering of accounts in the handling of resources.
In this sense, social and economic participants must prepare for the implementation of a policy of integrity, with the support of upper management, in order to articulate all anti-corruption controls and attain a setting of transparency, rendering of accounts, and integrity. They must develop and implement codes of ethics and conduct to guide their actions and aid in preventing inappropriate conduct that can generate conflicts and damage their organizational climate.
Companies and institutions must implement measures of ongoing improvement to combat potential acts of corruption and ensure that activities are carried out according to principles of ethics, integrity, transparency, and trustworthiness.
Lic. Arturo Morales Portas
Lic. Luis Verduzco Koloffon
Lic. Federico Amezcua Amezcua
Lic. Carlos López Patán
Ing. Ignacio Luna Tirado
Lic. Guillermo Narro Echegaray
Ing. Oscar Osorio Arechavaleta
Lic. Fernando Ramos Suárez
Ing. Fernando Javier Riedel Martínez
Ing. Roberto Rosas Puente
Lic. Antonio Rosas Treviño
Lic. Luis Alfonso Tirado Díaz
Lic. Carlos Amezcua Amezcua
Ing. Enrique Reyna Estrada
Ing. Juan Luis Rojas Moctezuma
Ing. Patricio Sada Muguerza
Dr. José Antonio Zavala Jiménez
Lic. José Miguel Ramos Rodríguez
DBA. Rogelio Herrera Sandoval
QFB. Roxana Rosas Puente
Mtro. Antonio Rosas Guinea
Lic. Felipe Espinosa de los Monteros Rico
Juan de Villafranca Andrade
Holds a degree in law from Universidad Iberoamericana and has broad experience in the public and private sectors.
In the public sector, served as commissioner of patents and trademarks at Mexico's patent office (IMPI), and director of the national registry of foreign investment at Mexico's Secretariat of Commerce and Industrial Development. At Mexico's Secretariat of Foreign Relations, progressed from deputy director of bilateral technical cooperation, director general of legal affairs, assistant to Secretary Fernando Solana, Mexican ambassador to Singapore, Brunei and Myanmar, to head of staff. Served as president of the General Assembly of the World Intellectual Property Organization (WIPO), and general comptroller of Mexico's Secretariat of Tourism.
In the private sector, has provided consulting in patents and trademarks, foreign investment, and business development. Directed Pegaso Media at Grupo Pegaso and Marking Services Incorporated.
Claudia Almazán Méndez
Regulatory Affairs Director
Holds a degree in Pharmacy from Autonomous National University of Mexico (UNAM).
Serves as a member of the subcommittee on health inputs for Mexico's federal bureau of standards and regulations.
Is a specialist in regulatory affairs. Has diplomas at Monitoring Clinical Trials and Hospitalary Pharmacy, both from UNAM.
Within AMELAF, is in charge of regulatory affairs and supplies.
Aida Rosas Pluma
Holds a bachelor's degree in Business Administration from Autonomous National University of Mexico (UNAM).
Has obtained experience in the international and private sector: in public relations at Scimpla S.A de C.V. (medical and laboratory equipment and instruments), and as assistant of direction, operations and administration at Marking Services de México (company dedicated to industrial signage).
Coordinated sales at EF Servicios en Educación Internacional; managed and coordinated the activities department at EF Education First, Tarrytown, New York.
Araceli Navia Vargas
Assistant to the Executive Director
Sonia López Martínez
Regulatory Affairs Assistant Director
Carlos Paz Chaparro
Technical Coordinator of Commissions
Susana Chaveste Toriz
Patricia García González
Coordinator of "Conéctate con AMELAF" Program